Katowice

• An Open label, Safety Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia Recruiting
  2023-509518-12-01 4 2024-04-16 Tardive dyskinesia
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-507039-39-00 5 2024-03-22 Moderate to Severe Plaque Psoriasis
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, d … Recruiting
  2024-516852-17-00 4 2023-11-13 Tardive dyskinesia
• A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting
  2022-502286-16-00 5 2023-10-27 Primary Generalized Tonic-Clonic Seizures
• Non-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mil … Recruiting
  2024-513214-34-00 4 2023-10-18 Distal Subungual Onychomycosis
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
• A Study of AG-946 in Participants With Anaemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS). Recruiting
  2022-500609-42-00 4 2023-02-24 Anemia Due to Lower-Risk Myelodysplastic Syndromes
• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis Recruiting
  2022-500345-25-00 4 2023-01-16 Moderately to severely active ulcerative colitis
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD … Recruiting
  2023-507379-23-00 10 2022-08-18 Generalized Myasthenia Gravis
• Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P … Recruiting
  2024-514617-35-00 4 2021-12-20 Progressive forms of Multiple Sclerosis
• Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBC Recruiting
  2023-503465-33-00 5 2020-07-03 Cholestasis
• A Phase 3 study of Hetrombopag in patients with low blood platelet count (thrombocytopenia) caused by chemotherapy Recruiting
  2025-524209-34-00 5 2026-05-20 Chemotherapy induced thrombocytopenia
• A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting
  2024-517337-41-00 5 2026-05-12 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus
• A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site … Recruiting
  2025-523757-33-00 4 2026-05-07 multiple sclerosis
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus Recruiting
  2025-524514-28-00 4 2026-05-06 Type 2 Diabetes Mellitus
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30 Obesity

Showing 121–144 of 706 trials